The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 77, Issue 6, 2014, Pages 965-974

  Othman, Ahmed A ^a   Haig, George ^b   Florian, Hana ^a   Locke, Charles ^a   Gertsik, Lev ^c   Dutta, Sandeep ^a  

^a ABBVIE INC   (United States)

^b CAIRO UNIVERSITY   (Egypt)

^c CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

ABT 288; cognitive deficits; schizophrenia; tolerability

Indexed keywords

ABT 288; HISTAMINE H3 RECEPTOR ANTAGONIST; 2-(4'-(5-METHYLHEXAHYDROPYRROLO(3,4-B)PYRROL-1-YL)BIPHENYL-4-YL)-2H-PYRIDAZIN-3-ONE; PYRIDAZINE DERIVATIVE; PYRROLE DERIVATIVE;

ABNORMAL DREAMING; ADULT; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; FEVER; HEADACHE; HUMAN; HYPOKALEMIA; INSOMNIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PAROSMIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; XEROSTOMIA; MIDDLE AGED;

ADULT; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H3 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; PYRROLES; SCHIZOPHRENIA;

EID: 84901336206     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12281     Document Type: Article

References (21)

1. Carpenter WT Jr, Heinrichs DW, Wagman AM,. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145: 578-583.
2. Owens DG, Miller P, Lawrie SM, Johnstone EC,. Pathogenesis of schizophrenia: a psychopathological perspective. Br J Psychiatry 2005; 186: 386-393.
3. Carpenter WT Jr,. Clinical constructs and therapeutic discovery. Schizophr Res 2004; 72: 69-73.
4. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA,. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64: 633-647.
5. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG,. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007; 64: 1115-1122.
6. Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD, the histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 2008; 154: 1166-1181.
7. Arrang JM, Garbarg M, Schwartz JC,. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832-837.
8. Blandina P, Bacciottini L, Giovannini MG, Mannaioni PF,. H3 receptor modulation of the release of neurotransmitters in vivo. In: Pharmacochemistry Library, eds, Rob L, Henk T,. Amsterdam: Elsevier, 1998; 27-40.
9. Hancock AA, Fox GB,. Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 2004; 13: 1237-1248.
10. Witkin JM, Nelson DL,. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 2004; 103: 1-20.
11. Esbenshade TA, Browman KE, Miller TR, Krueger KM, Komater-Roderwald VA, Zhang M, Fox GB, Rueter LE, Robb H, Radek RJ, Drescher KU, Fey TA, Bitner RS, Marsh KC, Polakowski JS, Zhao C, Cowart MD, Hancock AA, Sullivan JP, Brioni JD,. Pharmacological properties and pro-cognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 2012; 343: 233-245.
12. Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC,. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008; 30: 74-83.
13. Schwartz JC, the histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 2011; 163: 713-721.
14. Othman AA, Haig G, Florian H, Locke C, Zhang J, Dutta S,. Safety, tolerability and pharmacokinetics of the histamine H(3) receptor antagonist, ABT-288, in healthy young adults and elderly volunteers. Br J Clin Pharmacol 2013; 75: 1299-1311.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
16. Kay SR, Fiszbein A, Opler LA, the positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
17. Cutler NR,. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. J Clin Psychiatry 2001; 62 (Suppl. 5): 10-13; discussion 23-4.
18. Miller AL, Maas JW, Contreras S, Seleshi E, True JE, Bowden C, Castiglioni J,. Acute effects of neuroleptics on unmedicated schizophrenic patients and controls. Biol Psychiatry 1993; 34: 178-187.
19. Pokorny R, Finkel MJ, Robinson WT,. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm Res 1994; 11: 1221.
20. Seeman P,. Dopamine receptor sequences therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 1992; 7: 261-284.
21. Seeman P, Kapur S,. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci U S A 2000; 97: 7673-7675.